aducanumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
human origin 5464 1384260-65-4

Description:

MoleculeDescription

Molfile

Synonyms:

  • aducanumab
  • aducanumab-avwa
  • aduhelm
  • BIIB037
Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. ADUHELM reduces amyloid beta plaques, as evaluated in Studies 1, 2, and 3.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
June 7, 2021 FDA BIOGEN INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyloid related imaging abnormality-oedema/effusion 548.49 115.64 58 132 886 90627371
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 332.94 115.64 36 154 637 90627620

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyloid related imaging abnormality-oedema/effusion 454.09 134.41 51 130 651 42620503
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 364.35 134.41 42 139 663 42620491

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Amyloid related imaging abnormality-oedema/effusion 913.15 110.55 100 231 1475 110587493
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 610.38 110.55 69 262 1297 110587671
Superficial siderosis of central nervous system 171.57 110.55 18 313 147 110588821

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06DX03 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Other anti-dementia drugs
FDA MoA N0000193950 Amyloid Beta-directed Antibody Interactions
FDA EPC N0000193951 Amyloid Beta-directed Antibody

Related Drugs by ATC class:

N06DX Other anti-dementia drugs 3 drugs
donanemab-azbtlecanemabmemantine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alzheimer's disease indication 26929004 DOID:10652




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Amyloid beta A4 protein Membrane other ANTIBODY BINDING EC50 10 DRUG LABEL DRUG LABEL

External reference:

IDSource
105J35OE21 UNII
D10541 KEGG_DRUG
C4043101 UMLSCUI
CHEBI:755082 CHEBI
CHEMBL3039540 ChEMBL_ID
DB12274 DRUGBANK_ID
9838 INN_ID
C000600266 MESH_SUPPLEMENTAL_RECORD_UI
8325 IUPHAR_LIGAND_ID
1162583000 SNOMEDCT_US
1162609005 SNOMEDCT_US
4040592 VANDF
4040593 VANDF
347165 MMSL
39568 MMSL
d09759 MMSL
018764 NDDF
2557217 RXNORM

Pharmaceutical products:

None